Concepedia

Yu-Ping Luong

YL

Statistics

Publications

10

Citations

1.1K

H-Index

10

Active since

1994

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Yu-Ping Luong is an author at Vertex Pharmaceuticals (United States) specializing in medicine, drug discovery, and hepatitis.

Top concepts

Publications per year

1994–2007

10

Publications

10

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni, Susan J. Almquist, Randal A. Byrn et al. · Antimicrobial Agents and Chemotherapy · 2006 · 382 citations · Full text

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Kai Lin, Yu-Ping Luong et al. · Journal of Biological Chemistry · 2004 · 289 citations · Full text

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Cynthia A. Gates, B. Govinda Rao et al. · Journal of Biological Chemistry · 2005 · 216 citations · Full text

, , +14

Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization

Robert B. Perni, J. PITLIK, Shawn Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 62 citations · Full text

, , +9

Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants

Robert B. Perni, Luc J. Farmer, Kevin M. Cottrell et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 52 citations · Full text

, , +9

1–5 of 10